Dual Miners officially introduces 3 mining rigs
HELSINKI, Finland, April 13, 2022 (GLOBE NEWSWIRE) -- Dual Miners (www.dualminers.com/) have crossed the $20million USD mark in pre-orders. Dual Miners has announced the official introduction of three mining rigs that have the potential to change the worldwide crypto industry.
Dual Miners has used ASIC chip technology to create three solutions that are pre-configured for ease of use and promise a return on investment in as little as one month, led by some of the most experienced specialists in the Cryptocurrency mining industry.
DualPro, DualPro Max, and the most recent DualPremium are the company's current products, which support profitable operations on the blockchain of choice, according to a statement.
Dual Miners is a chip design and manufacturing firm established in London, with offices in Finland, South Korea, and Australia. It has a number of teams with in-depth understanding of, among other things, Blockchain technology and technological design.
The company provides graphics processing units to consumers in addition to providing crypto wallet development services. On three continents, the company has offices. Due to its extensive experience in the market, Dual Miners has acquired a solid name in the Blockchain industry.
As a result, Dual Miners will cover both shipping and import duties, allowing consumers to spend no more than the cost of the device and obtain everything they need to get started without incurring additional fees.
About Dual Miners
Dual miners, which bills itself as the world's first dual-mining firm, was founded in 2015 with the goal of developing and selling the world's first leading dual Cryptocurrency miners that use either SHA-256 or Scrypt technology, respectively. With the DualPro, we set out to provide more power at a lower cost than had previously been available. Dual Miners is headquartered in London, United Kingdom, and maintains offices in other locations throughout the globe. On the website www.dualminers.com, you may find out more about the company.
More details at www.dualminers.com/
(+358) 41 4001034
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ERYTECH to Present at the H.C. Wainwright Global Investment Conference17.5.2022 22:05:00 CEST | Press release
ERYTECHtoPresent at the H.C. WainwrightGlobal Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA. The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards. Mr. Beyen will be available for one-to-one meetings with investors on May 24, 25 and 26. If you would like to arrange a one-on-one meeting or register, please contact your conference representative. For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference websi
EVS COMMUNICATES THE RESULTS OF THE ORDINARY GENERAL MEETING17.5.2022 21:59:34 CEST | Press release
Publication on May17, 2022, after market closure Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVSCOMMUNICATES THERESULTSOFTHEORDINARYGENERAL MEETING EVS Broadcast Equipment SA, leading provider of live video production systems, held its Ordinary General Meeting on May 17, 2022. In total 73 shareholders representing 2,799,870 shares, or 19.5% of the company shares, attended by proxy the Ordinary General Meeting held physically at the company's registered office but for which the company had recommended its shareholders to attend by videoconference given the still sensitive health situation. All the resolutions have been approved, i.e.: - The remuneration report, the updated remuneration policy, the discharge of the Directors and the Auditor; - The 2021 annual accounts and the allocation of profits, including a total gross dividend of EUR 1.50 for fiscal year 2021 (such dividend is made up, on the one hand, of the i
SeaLegacy Celebrates the Inaugural Year of The Good Ocean17.5.2022 21:49:59 CEST | Press release
A unified, passionate group of businesses investing in SeaLegacy’s mission to protect the world’s oceans British Columbia, Canada, May 17, 2022 (GLOBE NEWSWIRE) -- When eight companies mostly unknown to one another came together for the first time in May of 2021, they were bound only by a commitment to protect our oceans and planet. Today, these founding members of The Good Ocean are actively supporting SeaLegacy’s commitment to ocean protection. "One of the questions I get asked the most is, 'What can I do?'" says SeaLegacy Co-Founder and President Cristina Mittermeier. "This question comes from individuals, and it also comes from businesses. Increasingly, consumers are demanding the products and services they support with their purchasing power be aligned with their desire to be accountable for their impact on earth. Members of The Good Ocean are addressing that demand and stepping into the crucial role businesses play in conservation work. Together, we are taking steps towards syste
Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Press release
STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition of Atrin Pharmaceuticals’ portfolio of candidate drugs, Aprea Therapeutics intends to shift its primary focus to the development of ATRN-119, a drug candidate that inhibits an important signaling pathway in DNA damage repair. ATRN-119 will soon be evaluated in clinical phase 1/2a studies in the treatment of malignant solid tumors, both as monotherapy and in combination with standard treatment. In parallel with the development of ATRN-119, separate programs are run with a second-generation ATR i
Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Pressemelding
STOCKHOLM, SVERIGE 17 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har förvärvat det privatägda amerikanska bioteknikbolaget Atrin Pharmaceuticals Inc. Aprea Therapeutics kommer nu att prioritera utvecklingen av Atrin Pharmaceuticals läkemedelskandidater, vilka utvecklas för att bekämpa cancersjukdomar genom att påverka de proteiner som är involverade i tumörers förmåga att reparera skador i sitt DNA. Efter förvärvet av Atrin Pharmaceuticals läkemedelsprojekt flyttar Aprea Therapeutics sitt primära fokus till utvecklingen av ATRN-119, en läkemedelskandidat som hämmar en viktig signaleringsväg vid reparation av DNA-skador. ATRN-119 kommer inom kort att börja studeras i kliniska fas 1/2a-studier vid behandling av maligna solida tumörer, både som monoterapi och i kombination med standardbehandling. Parallellt med utvecklingen av ATRN-119 bedrivs separata program med en andra generationens ATR-hämmare, ATRN-354, med poten